共 49 条
[1]
Choudhury NJ(2016)Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations J. Clin. Oncol. 34 2165-2171
[2]
Petrylak DP(2017)Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial Lancet 390 2266-2277
[3]
Robertson AG(2014)Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 315-322
[4]
Garnett MJ(2017)Comprehensive molecular characterization of muscle-invasive bladder cancer Cell 171 540-556.e525
[5]
Finn RS(2012)Systematic identification of genomic markers of drug sensitivity in cancer cells Nature 483 570-575
[6]
Hortobagyi GN(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol. 16 25-35
[7]
Damrauer JS(2016)Ribociclib as first-line therapy for HR-positive, advanced breast cancer N. Engl. J. Med. 375 1738-1748
[8]
Choi W(2014)Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology Proc. Natl. Acad. Sci. USA 111 3110-3115
[9]
Gallagher DJ(2014)Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy Cancer Cell 25 152-165
[10]
Milowsky MI(2008)Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting Cancer 113 1284-1293